Skip to main content
  • More from ADA
    • Diabetes
    • Diabetes Care
    • Clinical Diabetes
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, abridged
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Spectrum

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, Abridged
  • Browse
    • Issue Archive
    • Saved Searches
    • COVID-19 Article Collection
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, Abridged
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
  • More from ADA
    • Diabetes
    • Diabetes Care
    • Clinical Diabetes
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, abridged
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Spectrum
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, Abridged
  • Browse
    • Issue Archive
    • Saved Searches
    • COVID-19 Article Collection
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, Abridged
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
Departments

Has Research Optimized the Targeted Use of Weight Loss Surgery for Glucose Control?

  1. Jeffrey J. VanWormer, PhD
Diabetes Spectrum 2012 Nov; 25(4): 194-195. https://doi.org/10.2337/diaspect.25.4.194
PreviousNext
  • Article
  • Info & Metrics
  • PDF
Loading

For the foreseeable future, weight loss surgery is here to stay as a preferred medical treatment for obesity. Bariatric surgery is often described as a therapy of last resort, reserved only for those at the most extreme levels of obesity who have failed previous therapies. However, some are advocating expansion of the clinical indications for weight loss surgery to include more people with chronic diseases that respond favorably to surgically induced weight loss and lower thresholds of baseline body weight.

This is seemingly welcome news in the sense that surgery is the most effective obesity therapy currently available. Weight loss surgery patients can expect to lose roughly one-third of their preoperative body weight during the first postoperative year,1 and roughly two-thirds of patients can expect to maintain this weight loss during several years. Perhaps more importantly, at least from a disease-management perspective, several articles from a recent issue of the New England Journal of Medicine (NEJM) found that weight loss surgery was superior to standard medical treatment for type 2 diabetes.2,3 One of these studies2 found that, compared to the standard treatment group, the proportion of participants with normalized blood glucose after 1 year was nearly four times higher in the group that had weight loss surgery.

Despite these encouraging trial findings, it seems premature to view weight loss surgery as a strong public health strategy to combat obesity or type 2 diabetes. It does not prevent new obesity cases, and it requires more intensive medical care, sometimes secondary to major complications, that can increase short-term health care costs.

The NEJM studies were not considered “game changers” from a scientific perspective because of their relatively small sample sizes.4 But they likely made major inroads into the psyche of acceptability among the swelling ranks of U.S. adults suffering from the often doggedly inseparable comorbidities of persistent obesity and uncontrolled type 2 diabetes. As weight loss surgery starts to seem like a more acceptable, routine therapeutic option to this fast-growing segment of the U.S. adult population (and to their medical providers), more weight loss surgeries will be demanded and may become “the new normal” among those with type 2 diabetes and obesity and perhaps even among those with modest levels of excess body weight.

But there remain significant gaps in the literature on this topic that should give the medical and scientific communities pause before embracing this prognostication. The National Institutes of Health has recognized such research limitations and recently funded several large studies on the differential effectiveness of various weight loss surgery procedures on glucose control. This is undoubtedly a step in the right direction, but it remains to be seen whether these new studies will yield enough knowledge to justify changing clinical practice guidelines.

It seems tempting to overlook the progressive biological decrement in β-cell functioning that characterizes type 2 diabetes and usually requires more aggressive therapies as afflicted individuals age. Some researchers have suggested that clinicians often mistakenly leave patients with the impression that sustained weight loss is all this is needed to avoid antidiabetic medications and essentially arrest metabolic disease processes.5

But previous research seems to suggest that stark improvements in glucose control for a given weight loss tend to be greatest for those with highly elevated baseline blood glucose levels and even then only in the short term. These improvements usually erode over time, even among those who maintain their weight loss.6–8 A recent study found that diabetes recurrence or significant worsening of glucose control over 3 years occurred in 24% of weight loss surgery patients with type 2 diabetes who initially experienced successful diabetes resolution or significant improvement in glucose control.9 This trend was most pronounced in those at the lowest levels of preoperative BMI and those who regained the most weight.

The term “remission” is often used to describe the impact that weight loss surgery can have on type 2 diabetes. But what happens throughout many years or decades to the predictable metabolic patterns outlined above is largely unknown.

Perhaps the most crucial, but least understood, contributor to long-term surgical success points to the social-cognitive conditions that support sustained low-calorie eating and regular physical activity. At the end of the day, weight loss surgery works because it imposes strong bodily consequences on the amount and types of food people choose to eat (recognizing the additional contribution of nutritional malabsorption for some procedures).

Relatively little is known about how to prevent some weight loss surgery patients from 1) failing to adhere to the postoperative nutrition recommendations, 2) regaining weight, and 3) experiencing diabetes recurrence. In other words, weight loss surgery does not seem to directly alter the powerful environmental contingencies or resolve underlying emotional coping issues that encourage or maintain overeating for some individuals. The degree to which these behavioral phenomena operate similarly and can be modified in weight loss surgery patients with type 2 diabetes needs further exploration because the medical and economic consequences of surgical failures will arguably be most severe in this group.

Given the high stakes of weight loss surgery in general and for individuals with type 2 diabetes in particular, clinicians hope to learn more about the relative advantages and disadvantages of the various types of available procedures and their effects on long-term glycemic control. What subgroups of type 2 diabetes patients have the highest probability of success with each type of procedure? Which have the highest probability of failure? Why? Given the medical complexities of this population, are there additional barriers to sustained lifestyle changes not yet observed or that are particularly challenging to modify in typical home/work/leisure environments?

The widespread but targeted application of weight loss surgery for glucose control may eventually be shown to improve the American public's health, but there seems to be much room still for optimization. A conservative approach is urged on this front before more methodologically rigorous studies can confirm that weight loss surgery results in clear, consistent, and lasting glucose-control benefits and improved quality of life above and beyond standard medical therapies for individuals with type 2 diabetes.

Footnotes

  • Jeffrey J. VanWormer, PhD, is an associate research scientist in the Epidemiology Research Center at the Marshfield Clinic Research Foundation in Marshfield, Wis. He is also an associate editor of Diabetes Spectrum.

  • American Diabetes Association(R) Inc., 2012

References

  1. ↵
    1. Wadden TA,
    2. Stunkard AJ
    1. Latifi R,
    2. Kellum JM,
    3. DeMaria EJ,
    4. Sugerman HJ
    : Surgical treatment of obesity. In Handbook of Obesity Treatment. 3rd ed. Wadden TA, Stunkard AJ, Eds. New York, Guilford Press, 2002, p. 339–356
  2. ↵
    1. Schauer PR,
    2. Kashyap SR,
    3. Wolski K,
    4. Brethauer SA,
    5. Kirwan JP,
    6. Pothier CE,
    7. Thomas S,
    8. Abood B,
    9. Nissen SE,
    10. Bhatt DL
    : Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 366:1567–1576, 2012
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Mingrone G,
    2. Panunzi S,
    3. De Gaetano A,
    4. Guidone C,
    5. Iaconelli A,
    6. Leccesi L,
    7. Nanni G,
    8. Pomp A,
    9. Castagneto M,
    10. Ghirlanda G,
    11. Rubino F
    : Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 366:1577–1585, 2012
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. Grady D
    : Surgery for diabetes may be better than standard treatment [article online]. Available from www.nytimes.com/2012/03/27/science/to-combat-diabetes-weight-loss-surgery-works-better-than-medicine-studies-find.html. Accessed 30 July 2012
  5. ↵
    1. Franz MJ,
    2. Pastors JG,
    3. Warshaw H,
    4. Daly AE
    : Does “diet” fail? Clinical Diabetes 18:162–168, 2000
    OpenUrl
  6. ↵
    1. U.K. Prospective Diabetes Study Group
    : Response of fasting plasma glucose to diet therapy in newly presenting type II diabetic patients. Metabolism 39:905–912, 1990
    OpenUrlCrossRefPubMedWeb of Science
    1. Watts NB,
    2. Spanheimer RG,
    3. DiGirolamo M,
    4. Gebhart SS,
    5. Musey VC,
    6. Siddiq YK,
    7. Phillips LS
    : Prediction of glucose response to weight loss in patients with non-insulin-dependent diabetes mellitus. Arch Intern Med 150:803–806, 1990
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    1. Wing RR,
    2. Koeske R,
    3. Epstein LH,
    4. Nowalk MP,
    5. Gooding W,
    6. Becker D
    : Long-term effects of modest weight loss in type II diabetic patients. Arch Intern Med 147:1749–1753, 1987
    OpenUrlCrossRefPubMedWeb of Science
  8. ↵
    1. DiGiorgi M,
    2. Rosen DJ,
    3. Choi JJ,
    4. Milone L,
    5. Schrope B,
    6. Olivero-Rivera L,
    7. Restuccia N,
    8. Yuen S,
    9. Fisk M,
    10. Inabnet WB,
    11. Bessler M
    : Re-emergence of diabetes after gastric bypass in patients with mid- to long-term follow-up. Surg Obes Relat Dis 6:249–253, 2010
    OpenUrlCrossRefPubMedWeb of Science
PreviousNext
Back to top
Diabetes Spectrum: 25 (4)

In this Issue

November 2012, 25(4)
  • Table of Contents
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Spectrum.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Has Research Optimized the Targeted Use of Weight Loss Surgery for Glucose Control?
(Your Name) has forwarded a page to you from Diabetes Spectrum
(Your Name) thought you would like to see this page from the Diabetes Spectrum web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Has Research Optimized the Targeted Use of Weight Loss Surgery for Glucose Control?
Jeffrey J. VanWormer
Diabetes Spectrum Nov 2012, 25 (4) 194-195; DOI: 10.2337/diaspect.25.4.194

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Has Research Optimized the Targeted Use of Weight Loss Surgery for Glucose Control?
Jeffrey J. VanWormer
Diabetes Spectrum Nov 2012, 25 (4) 194-195; DOI: 10.2337/diaspect.25.4.194
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Footnotes
    • References
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

Departments

  • Smart Connected Insulin Pens, Caps, and Attachments: A Review of the Future of Diabetes Technology
  • Brief Literature Review: The Potential of Diabetes Technology to Improve Sleep in Youth With Type 1 Diabetes and Their Parents: An Unanticipated Benefit of Hybrid Closed-Loop Insulin Delivery Systems
  • Mental Health and Behavioral Screening in Pediatric Type 1 Diabetes
Show more Departments

Editorial

  • Finding My Diabetes Community
  • Oh, What Times We Live In!
  • Diabetes Spectrum: Past, Present, and Future
Show more Editorial

Similar Articles

Navigate

  • Current Issue
  • Papers in Press
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Diabetes Care
  • Clinical Diabetes
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Spectrum Print ISSN: 1040-9165, Online ISSN: 1944-7353.